There are few data available to assess the safety during pregnancy of agents currently used to treat asthma and allergic disorders.
The American College of Allergy Asthma, and Immunology Registry for Allergic, Asthmatic Pregnant Patients (RAAPP) was established to provide data to assess the hypothesis that the aggressive treatment of asthma and allergy in pregnant women will encourage positive outcomes for mother and baby.
Currently in progress is a pilot study of 800 patients who require inhaled corticosteroids during pregnancy.
The major outcome variable for the pilot study is small for gestational age, defined as a birth weight below the 10th percentile for gestational age.
After evaluation of these data, the Registry will probably be opened to general enrollment of any pregnant patient with allergy and/or asthma, regardless of medication use.
When completed, RAAPP will enable physicians to evaluate the safety of medications commonly used by allergists to treat allergy and asthma during pregnancy.
Mots-clés Pascal : Asthme, Allergie, Gestation, Chimiothérapie, Traitement mère, Toxicité, Accouchement, Fonction respiratoire, Surveillance, Pharmacovigilance, Homme, Etats Unis, Amérique du Nord, Amérique, Appareil respiratoire pathologie, Bronchopneumopathie obstructive, Immunopathologie, Nouveau né pathologie, Foetus pathologie, Mère pathologie
Mots-clés Pascal anglais : Asthma, Allergy, Pregnancy, Chemotherapy, Maternal treatment, Toxicity, Delivery, Lung function, Surveillance, Pharmacovigilance, Human, United States, North America, America, Respiratory disease, Obstructive pulmonary disease, Immunopathology, Newborn diseases, Fetal diseases, Maternal diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0159274
Code Inist : 002B20F02. Création : 16/11/1999.